We compared the angiotensin-neprilysin inhibitor LCZ696 ( 400 mg daily ) with the angiotensin-converting enzyme inhibitor enalapril ( 20 mg daily ) in 8399 patients with heart failure and reduced ejection fraction in a double-blind trial .